BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32758419)

  • 1. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.
    Li W; Qiu S; Chen J; Jiang S; Chen W; Jiang J; Wang F; Si W; Shu Y; Wei P; Fan G; Tian R; Wu H; Xu C; Wang H
    Immunity; 2020 Aug; 53(2):456-470.e6. PubMed ID: 32758419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunoproteomic approach to characterize the CAR interactome and signalosome.
    Ramello MC; Benzaïd I; Kuenzi BM; Lienlaf-Moreno M; Kandell WM; Santiago DN; Pabón-Saldaña M; Darville L; Fang B; Rix U; Yoder S; Berglund A; Koomen JM; Haura EB; Abate-Daga D
    Sci Signal; 2019 Feb; 12(568):. PubMed ID: 30755478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
    Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A; Liu F; Young RM; June CH; Posey AD
    J Clin Invest; 2020 Jun; 130(6):3087-3097. PubMed ID: 32069268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
    Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
    Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
    Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
    Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
    FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
    Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
    Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
    JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
    Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
    Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.